Thyroid hormone receptor beta inhibits the PI3K-Akt-mTOR signaling axis in anaplastic thyroid cancer via genomic mechanisms

Authors: Cole D. Davidson ^{1,2}, Eric L. Bolf ^{1,2}, Noelle E. Gillis ^{1,2}, Lauren M. Cozzens ¹, Jennifer A. Tomczak ¹, and Frances E. Carr ^{1,2,*}

¹ *Department of Pharmacology, Larner College of Medicine, Burlington, Vermont.*

² *University of Vermont Cancer Center, Burlington, Vermont.*

* *Corresponding author, Email: Frances.Carr@med.uvm.edu*

Short title: TRβ Inhibits PI3K Signaling via Genomic Mechanisms

Keywords: Anaplastic thyroid cancer, PI3K, PI3K inhibitor, thyroid hormone receptor, receptor tyrosine kinase, PI3K phosphatase

Cole D. Davidson: Conceptualization, Formal analysis, Investigation, Writing – Original draft preparation, Visualization. **Eric L. Bolf:** Conceptualization, Formal analysis, Investigation, Writing – Review & editing. **Noelle E. Gillis:** Formal analysis, Investigation, Writing – Review & editing. **Lauren M. Cozzens:** Formal analysis, Investigation. **Jennifer A. Tomczak:** Investigation, Writing – Review & editing. **Frances E. Carr:** Resources, Writing – Review & editing, Supervision, Project administration, Funding acquisition.

The research reported here was supported by grants from National Institutes of Health U54 GM115516 for the Northern New England Clinical and Translational Research Network; National Cancer Institute 1F99CA245796-01; UVM Cancer Center-Lake Champlain Cancer Research Organization (C3) 12577-21; and UVM Larner College of Medicine.

No potential conflicts of interest were disclosed.

Abstract:

Thyroid cancer is the most common endocrine malignancy, and the global incidence has increased rapidly over the past few decades. Anaplastic thyroid cancer (ATC) is highly aggressive, dedifferentiated, and patients have a median survival of fewer than six months. Oncogenic alterations in ATC include aberrant PI3K signaling through receptor tyrosine kinase (RTK) amplification, loss of phosphoinositide phosphatase expression and function, and Akt amplification. Furthermore, the loss of expression of the tumor suppressor thyroid hormone receptor beta (TR β) is strongly associated with ATC. TR β is known to suppress PI3K in follicular thyroid cancer and breast cancer by binding to the PI3K regulatory subunit p85 α . However, the role of TR β in suppressing PI3K signaling in ATC is not completely delineated. Here we report that TR β indeed suppresses PI3K signaling in ATC through unreported genomic mechanisms including a decrease in RTK expression and increase in phosphoinositide and Akt phosphatase expression. Furthermore, the reintroduction and activation of TR β in ATC enables an increase in the efficacy of the competitive PI3K inhibitors LY294002 and buparlisib on cell viability, migration, and suppression of PI3K signaling. These findings not only uncover additional tumor suppressor mechanisms of TR β but shed light into the implication of TR β status and activation on inhibitor efficacy in ATC tumors.

Abbreviations:

Akt, protein kinase B; ATC, anaplastic thyroid cancer; AXL, tyrosine-protein kinase receptor UFO; EGFR, epidermal growth factor receptor; ELISA, enzyme-linked immunosorbent assay; FGFR3/4/L1, fibroblast growth factor receptor 3/4/like 1; FTC, follicular thyroid cancer; GSK3 β ,

glycogen synthase kinase 3 beta; GYS1, glycogen synthase 1; HER2, receptor tyrosine-protein kinase erbB-2; HER3, receptor tyrosine-protein kinase erbB-3; INPP4B, inositol polyphosphate 4-phosphatase type II; INPP5J, phosphatidylinositol 4,5-bisphosphate 5-phosphatase A; JAK1, janus kinase 1; mTORC1/2, mammalian target of rapamycin complex 1/2; p70S6K, ribosomal protein S6 kinase beta-1 PDK1, 3-phosphoinositide dependent protein kinase 1; PDTC, poorly differentiated thyroid cancer; PEKHA2, tandem-PH-domain-containing protein-2; PHLPP1, PH domain and leucine-rich repeat-protein phosphatase 1; PI(3,4)P₂, phosphatidylinositol 3,4-bisphosphate; PI(3)P, phosphatidylinositol 3-phosphate; PI(4,5)P₂, phosphatidylinositol 4,5-bisphosphate; PI3K, phosphoinositide 3 kinase; PIP₃, phosphatidylinositol 3,4,5 trisphosphate; PPP2R5B, protein phosphatase 2R5B; PTC, papillary thyroid cancer; PTEN, phosphatase and tensin homolog; PTPN13, protein-tyrosine-phosphatase-like protein-1; ROR1, neurotrophic tyrosine kinase receptor-related 1; RT-qPCR, reverse transcriptase quantitative polymerase chain reaction; RTK, receptor tyrosine kinase; RUNX2, runt-related transcription factor 2; STAT1, signal transducer and activator of transcription 1; T₃, triiodothyronine; TR β , thyroid hormone receptor beta

1. Introduction

Thyroid cancer is the most common endocrine malignancy, and the incidence has been rapidly increasing the past few decades (1). While the overall prognosis for thyroid cancer is generally favorable, patients with the most aggressive and dedifferentiated subtype, anaplastic thyroid cancer (ATC), have a median survival of three to five months (2). The current most effective treatments for ATC patients increase survival time by only a few months as drug resistance and

tumor recurrence often develop (3). Therefore, there is an unmet need for more precise understanding of the molecular etiology of ATC tumorigenesis and new strategies for improving patient outcome.

Phosphoinositide 3 kinase (PI3K) signaling is a prominent molecular driver for aggressive and poorly differentiated thyroid cancers such as ATC (4). PI3K is recruited to the plasma membrane by phosphorylated, ligand-bound receptor tyrosine kinases (RTKs). PI3K phosphorylates the membrane lipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to PIP₃, which recruits 3-phosphoinositide dependent protein kinase 1 (PDK1) and the mammalian target of rapamycin complex 2 (mTORC2) to the plasma membrane to phosphorylate Akt on thr308 and ser473, respectively. Phosphatase and tensin homolog (PTEN) is a tumor suppressor that dephosphorylates PIP₃ back to PI(4,5)P₂. Akt phosphorylates a myriad of targets that are involved in cell cycle progression and survival signaling. In addition, Akt leads to the activation of mTORC1, which phosphorylates targets such as p70S6K that ultimately lead to the activation and assembly of translation factors for protein synthesis and cell growth (5,6). Multiple genes are either mutated or amplified within the PI3K pathway in ATC. Frequent alterations include amplification of RTKs such as epidermal growth factor (EGFR), amplification or gain-of-function mutations in *PIK3CA* (PI3K), loss-of-function mutations or decreased expression of *PTEN*, and amplification of *AKT1* (7-10).

In addition to the canonical mechanisms of PI3K regulation, there are a multitude of other factors that regulate the pathway. These factors include members of the nuclear hormone receptor family including estrogen, androgen, and thyroid hormone receptors (11-13). Our work has demonstrated that thyroid hormone receptor beta (TR β) acts as a tumor suppressor in ATC

through repression of several pathways important for tumor growth (14,15). However, the potential for TR β to exhibit tumor suppression in ATC by suppressing PI3K is not fully understood. Multiple groups have reported the potential for TR β to bind to the regulatory subunit of PI3K, p85 α , to inhibit phosphorylation of PI(4,5)P₂ to PIP₃ (16-18). While these mechanisms help explain the potential for TR β to inhibit PI3K in certain cancer models, there may be other mechanisms of TR β -mediated suppression. While TR β has been shown to inhibit PI3K via nongenomic mechanisms in breast (19) and follicular thyroid (20,21) cancer, it is unknown if this mechanism or unexplored genomic mechanisms occur in ATC. Therefore, we sought to better understand the mechanism of TR β -mediated suppression of PI3K signaling in ATC using a TR β -expression model. Moreover, we tested the efficacy of the PI3K inhibitors LY294002 and buparlisib in cells with or without TR β expression. These findings present previously unexplored mechanisms of the tumor suppression by TR β , the role of TR β in ATC, as well as the implication of TR β expression status in response to PI3K-targeted therapeutic intervention.

2. Materials and methods:

2.1. Culture of thyroid cell lines

Cells were cultured in RPMI 1640 growth media with L-glutamine (300 mg/L), sodium pyruvate and nonessential amino acids (1%) (Corning Inc, Corning, NY, USA), supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) and penicillin-streptomycin (200 IU/L) (Corning) at 37°C, 5% CO₂, and 100% humidity. Lentivirally modified SW1736 cells were generated as described (15,22) with either an empty vector (SW-EV) or to overexpress TR β (SW-TR β). SW-EV and SW-TR β were grown in the above conditions with the addition of 2 μ g/ml

puromycin (Gold Bio, St Louis, MO, USA). SW1736 and KTC-2 were authenticated by the Vermont Integrative Genomics Resource at the University of Vermont (Burlington, Vermont) using short tandem repeat profiles and Promega GenePrint10 System (SW1736, May 2019; KTC-2, October 2019). 8505C, OCUT-2, and CUTC60 were authenticated by University of Colorado by short tandem repeat profiles (8505C, June 2013; OCUT-2, June 2018; CUTC60, November 2018).

2.2. Cell culture reagents

Triiodothyronine (T₃) was purchased from Sigma (St. Louis, MO, USA) and dissolved in 1 N NaOH and diluted to 10 nM in cell culture medium at the time of each application. LY294002 and buparlisib were purchased from MedChemExpress (Monmouth Junction, NJ, USA). LY294002 was dissolved in 100% ethanol and buparlisib was dissolved in 100% DMSO prior to indicated dilutions for cell culture experiments.

2.3. Immunoblot analysis

Proteins were isolated from whole cells in lysis buffer (20mM Tris-HCl (pH 8), 137mM NaCl, 10% glycerol, 1% Triton X-100, and 2mM EDTA) containing Protease Inhibitor Cocktail (Catalogue Number 78410) (Thermo Fisher Scientific), 1 mM Na₃VO₄, and 1 mM PMSF (Sigma). Proteins were quantified via Pierce Coomassie Plus (Bradford) Assay (Thermo Fisher Scientific), and 25 µg of protein per sample were resolved by polyacrylamide gel electrophoresis on 10% Tris-Glycine gels (Catalogue Number XP00105BOX) (Thermo Fisher Scientific) and immobilized onto nitrocellulose membranes (GE Healthcare, Chicago, IL, USA) by electroblot (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were blocked with 5% w/v BSA in TBS and 0.1% v/v Tween20 (Gold Bio, St

Louis, MO, USA) for one hour at room temperature and incubated with primary antibodies overnight (Supplementary Table 1); immunoreactive proteins were detected by enhanced chemiluminescence (Thermo Scientific) on a ChemiDoc XRS+ (Bio-Rad Laboratories). Densitometry analysis in Figure 4B was performed using ImageJ (NIH, Bethesda, MD, USA).

2.4. Measurement of Akt phosphorylation by ELISA

Akt serine 473 phosphorylation was measured using Pathscan phospho-Akt1 sandwich ELISA kit, according to the manufacturer's instructions (Cell Signaling Technology, Danvers, MA, USA). Samples were prepared from cells treated with 10 nM T₃ for 24 hours and then 1 hour incubation in the presence or absence of 1 or 10 μM LY294002. 100 μl of samples containing equal amount of protein were applied to each well.

2.5. Measurement of PI3K activity by ELISA

PI3K activity was determined using a commercially available PI3K ELISA kit (Echelon Biosciences Inc., Salt Lake City, UT) according to the manufacturer's instructions. Briefly, after drug treatment, cells were washed in ice-cold PBS and lysed in 500 μl ice-cold lysis buffer (137 mM NaCl, 20 mM Tris-HCl (pH 7.4), 1 mM CaCl₂, 1 mM MgCl₂, 1 mM Na₃VO₄, 1% NP-40 and 1 mM PMSF). PI3K was then immunoprecipitated with 5 μl of antibody (anti-p85α, MilliporeSigma, Burlington, MA, USA) and 60 μl of Pierce Protein A/G magnetic beads (Thermo Scientific). PI3K activity in the immunoprecipitates was then assayed by PI3K ELISA according to the manufacturer's instructions. The spectrophotometric data were obtained using a Synergy 2 Multi-Detection Microplate Reader (Agilent Technologies, Santa Clara, CA, USA) at a wavelength of 450 nm. The

protein concentrations of cellular lysates were determined by Bradford assay as described above.

The activity of PI3K was corrected for protein content.

2.6. RNA-seq data analysis of PI3K pathway intermediates

Previously published RNA-seq data was used to determine expression levels of genes within the PI3K pathway (15). Construction of the PI3K signaling genes of interest for our study was based on the curated IPA pathway gene set. Additional genes of interest were added based on literature search and cancer relevance. Normalized transcript counts generated with DESeq2 were used to calculate fold change compared to the control condition (SW-EV -T₃). Raw and processed expression data can be found in the Gene Expression Omnibus (GEO) database under accession number GSE150364.

2.7. Analysis of thyroid cancer patient sample data

Publicly available microarray expression data, deposited in the GEO Database (GSE76039, GSE3467, GSE82208), were analyzed using GEOR2 (www.ncbi.nlm.nih.gov/gds) to reveal differential expression of genes relevant to PI3K signaling across the spectrum of thyroid cancers.

2.8. RNA extraction and quantitative Real-Time PCR (qRT-PCR)

Total RNA was extracted using RNeasy Plus Kit (Qiagen) according to manufacturer's protocol. cDNA was then generated using the 5X RT Mastermix (ABM, Vancouver, Canada). Gene expression to validate RNA-seq analysis was quantified by qRT-PCR using BrightGreen 2X qPCR MasterMix (ABM, Vancouver, Canada) on a QuantStudio 3 real-time PCR system (Thermo Fisher

Scientific). Fold change in gene expression compared to endogenous controls was calculated using the ddCT method. Primer sequences are indicated in Supplemental Table 2.

2.9. *In vitro* cell viability assay

The cell viability assay was performed by plating 1.0×10^4 SW-EV or SW-TR β cells into 12 well (22.1 mm) tissue culture dishes. After adhering overnight, the cells were treated with 10 nM T₃ and LY294002, buparlisib, or vehicle at the indicated concentrations. Every day after treatment for four days, the medium was removed, cells were washed with PBS and lifted with trypsin (Thermo Scientific), and the number of surviving cells was counted with a hemocytometer.

2.10. Migration assay

Cell migration was determined by wound healing assay. Cells were plated and allowed to grow to 100% confluency. Two hours prior to scratching, cells were treated with 10 μ g/ml Mitomycin C (Sigma, MO, USA) dissolved in H₂O. A scratch was performed with a P1000 pipette tip and debris was washed away with PBS. Migration media was supplemented with 10 nM T₃ and LY294002 or vehicle. Images were obtained using a Canon digital camera connected to an Axiovert inverted microscope (Carl Zeiss, Oberkochen, Germany) at 0, 24, 48, and 72 hours. Wound closure was measured using ImageJ macro “Wound Healing Tool” (http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool). Values were normalized so that the initial scratch was 0% closure.

2.11. Statistics

All statistical analyses were performed using GraphPad Prism software. Paired comparisons were conducted by Student's t-test. Group comparisons were made by one-way ANOVA followed by Dunnett's or Tukey's multiple comparison test as appropriate. Two-way ANOVA followed by a Tukey's multiple comparison test was conducted for multigroup analysis. Data are represented as mean $\pm$ standard deviation. Area under the curve (AUC) at the 95th confidence interval was used to evaluate statistical differences in growth and migration assays.

3. Results

3.1 Rapid thyroid hormone receptor action fails to suppress PI3K in ATC cells

TR β is a known suppressor of the PI3K signaling pathway in breast and follicular thyroid cancer. This has been previously described as a nongenomic mechanism in which TR β binds to the regulatory subunit of PI3K, p85 α , preventing recruitment to ligand-bound RTKs (13). This action is rapid, and the addition of the thyroid hormone triiodothyronine (T₃) modulates the response within 15-30 minutes (23). Therefore, we sought to evaluate the impact of short term T₃ treatment in the SW1736 cell line with restored stable expression of TR β or an empty vector (EV) control. Analysis of pAkt and pmTOR by Western blot surprisingly revealed a minimal impact of TR β with or without T₃ on PI3K suppression (Fig. 1A). To validate these results, we performed a PI3K immunoprecipitation followed by ELISA to test the ability of PI3K to catalyze the phosphorylation of PI(4,5)P₂ to PIP₃ following T₃ treatment. Again, we observed a modest but insignificant decrease in PIP₃ production in the presence of TR β and T₃ (Fig. 1B).

3.2 Long-term T₃ treatment suppresses PI3K signaling in ATC cells

Since short-term T_3 treatment did not suppress PI3K activity in our cell line model, we hypothesized that long-term T_3 treatment may enable TR β -mediated suppression of PI3K signaling. Therefore, we treated our EV and TR β cells with T_3 for 24 hours then measured pAkt, pmTOR, and pp70S6K levels by Western blot (Fig. 2A). The SW-TR β cells treated with T_3 exhibited a marked decrease in pAkt on serine 473 but not threonine 308. Serine 473 phosphorylation induces a substantial increase in Akt activity following growth factor stimulation and plays a role in regulating substrate specificity (24). Additionally, there was a modest reduction in pP70S6K, a kinase further downstream of Akt. To validate the observed Akt ser473 dephosphorylation, we conducted a sandwich ELISA with our EV and TR β cells following 24-hour T_3 treatment (Fig. 2B); pAkt (ser473) was again reduced with liganded-TR β .

In order to test the impact of long-term T_3 exposure and heightened TR β expression we measured a well-studied downstream effector, glycogen synthase kinase 3 beta (GSK3 β) and its substrate glycogen synthase 1 (GYS1). GSK3 β is a multi-substrate kinase and, importantly, is implicated in the progression of numerous cancers including ATC (25,26). We observed a modest increase in phosphorylated, and thus inactivated, GYS1 in the presence of T_3 and a marked increase of pGYS1 in the presence of both TR β and T_3 (Fig. 2C). Since TR β - T_3 treatment suppressed both Akt-mTOR-P70S6K and Akt-GSK3 β -GYS1 pathways, these data are suggestive of a requirement for both thyroid hormone and TR β to achieve robust inactivation of PI3K signaling as observed through two separate pathways downstream of Akt.

3.3 Liganded-TR β transcriptionally remodels the PI3K signaling landscape

Since a long-term T_3 treatment was needed for robust suppression of PI3K signaling in our cell line model, we hypothesized that TR β may be regulating the expression of key components of this pathway. In order to better understand the extent to which TR β suppresses PI3K signaling through genomic mechanisms, we leveraged our RNA-sequencing data performed on our EV and TR β cell lines following 24 hours of T_3 treatment (15). Numerous genes involved in the PI3K pathway were determined to be differentially expressed in the presence of both T_3 and TR β (Fig. 3A-C).

Receptor tyrosine kinase gene expression was reduced in the TR β - T_3 group, including HER3 (*ERBB3*), fibroblast growth factor receptor isoforms (*FGFR3*, *FGFR4*, *FGFRL1*), neurotrophic tyrosine kinase receptor-related 1 (*ROR1*), and tyrosine-protein kinase receptor UFO (*AXL*).

While *PTEN* expression was not increased, other membrane-bound phosphoinositide phosphatases did increase including phosphatidylinositol 4,5-bisphosphate 5-phosphatase A (*INPP5J*), and inositol polyphosphate 4-phosphatase type II (*INPP4B*), which dephosphorylate PIP₃ to PI(3,4)P₂ and PI(3,4)P₂ to PI(3)P, respectively (27). There was also an increase in expression of cytosolic phosphatases that dephosphorylate Akt primarily on ser473, including tandem-PH-domain-containing protein-2 and protein-tyrosine-phosphatase-like protein-1 (*PLEKHA2* and *PTPN13*), the R5B localization subunit of protein phosphatase 2 (*PPP2R5B*), and PH domain and leucine-rich repeat-protein phosphatase 1 (*PHLPP1*) (28-30). In addition to these genes that serve to regulate PI3K activation and subsequent Akt phosphorylation, genes involved in PI3K recruitment and stabilization, mTORC regulation, and translation factors were found to be differentially regulated in the TR β - T_3 group (Supplemental Fig. 1A-D and Table 3). The fold change

of a subset of the differentially expressed genes were validated via RT-qPCR (Supplemental Fig. 2).

3.4 Endogenous TR β expression in ATC cells correlates with low pAkt ser 473 and high PI3K-Akt signaling phosphatase expression

Following our RNA-sequencing findings in transduced SW1736 cells, we next questioned if level of endogenous TR β expression correlates with reduced Akt phosphorylation and increased PI3K-Akt phosphatase expression. We demonstrated a significant inverse correlation between TR β expression and Akt phosphorylation as shown by immunoblot (Fig. 4A and B). Furthermore, 8505C with the highest level of endogenous TR β also had the highest expression of the phosphoinositide phosphatases *INPP4B* and *INPP5J* as well as the pAkt ser473 phosphatase *PHLLP1* (Fig. 4C). These findings illustrate the trend between TR β and expression of tumor suppressive genes in PI3K signaling in a genetically diverse set of ATC cell lines (Supplemental Table 4).

3.5 PI3K signaling genes regulated by TR β in SW1736 cells are aberrantly expressed in patient thyroid cancer samples

Next, we used expression data from matched normal tissue and papillary, follicular, poorly differentiated, and anaplastic thyroid carcinomas to determine if any of the PI3K regulators we revealed to be altered by TR β -T₃ treatment exhibited differential expression in different thyroid cancer subtypes (31-33). The patient microarray data revealed that the RTKs ERBB3 (HER3), ROR1, and AXL expression levels correlate with TC subtype where expression is highest in the

more aggressive tumors (Fig. 5A). Conversely, phosphatase expression is highest in matched normal tissue and differentiated thyroid tumors (Fig. 5B). Interestingly, expression of FGFR4 and FGFR1 were lowest in the more aggressive PDTC and ATC populations. We next analyzed gene expression data for TR β and markers of differentiated thyroid cells to demonstrate the connection between TR β -T₃ presence with increased RTK and decreased phosphatase expression. *THRB* (TR β) and genes encoding enzymes and transporters for thyroid hormone synthesis were coordinately lost in FTC, PDTC, and ATC patient samples (Fig. 5C). As demonstrated previously, TR β protein is significantly reduced in FTC, PDTC, and ATC patients (14), a finding that may contribute to the gene expression data presented here.

3.6 TR β and T₃ inhibit cell viability and migration in serum-activated cells

PI3K signaling fuels cancer progression by stimulating cell survival, proliferation, and migration. We previously demonstrated that TR β inhibits SW1736 proliferation in charcoal-stripped media, an observation that was dependent upon T₃ stimulation (15). To achieve phenotypic confirmation of our sequencing results, we challenged our engineered cells in full serum (10%) media with or without additional 10 nM T₃ to measure a functional consequence of PI3K inhibition. Even in the presence of full serum and activated RTKs, the TR β group rendered the SW1736 cells less viable (Fig. 6A and B). In accordance with the RNA-sequencing data, T₃ is necessary for maximum inhibition of cell viability by TR β . Additionally, we challenged our cells to migrate in the presence of liganded-TR β . TR β cells were unable to effectively migrate to close the wound compared to the EV cells (Fig. 6C-E). These findings are similar to what we observed previously in experiments

using charcoal-stripped, growth-deprived media, thus indicating the absolute requirement of TR β to inhibit cell viability and migration.

3.7 TR β improves PI3K inhibitor efficacy

In order to further test our hypothesis that TR β suppresses PI3K signaling in ATC cells, we established the efficacy of small molecule competitive PI3K inhibitors on cell cytotoxicity. Both LY294002 and buparlisib compete for the ATP-binding site of PI3K, preventing PIP₂ phosphorylation. It should be noted that buparlisib is 27 times more potent than LY294002 (IC₅₀ of 52 nM and 1.4 μ M, respectively (34)). The TR β cells showed an improved response to LY294002, with an EC₅₀ value nearly 5-fold less than the EV cells (Fig. 7A). In addition, the TR β cells were nearly 25-fold more sensitive to the PI3K inhibitor buparlisib than the EV cells (Supplemental Fig. 3). In concordance with the RNA sequencing and cell viability data, TR β requires T₃ to fully exert the tumor suppressive profile; LY294002 efficacy was not increased in SW-TR β cells lacking 10 nM T₃ (Supplemental Fig. 4). LY294002 efficacy was also enhanced in the TR β cells as measured by migration assay at both 1 and 10 μ M (Fig. 7B-D).

3.8 TR β enhances PI3K inhibitor inactivation of the PI3K-Akt-mTOR axis

To further confirm that TR β is specifically inhibiting the PI3K signaling pathway, we challenged our cells with LY294002 and buparlisib and measured pAkt, pmTOR, and pp70S6K levels following 24 hours of T₃ treatment. LY294002 and buparlisib were able to blunt Akt thr308 phosphorylation in both cell lines, but there was a marked decrease in levels of pAkt (ser473), pmTOR (ser2448 and ser2481), and pp70S6K (Fig. 8A and Supplemental Fig. 5A). We validated these findings with

a pAkt (ser473) sandwich ELISA and detected lower levels of pAkt in the LY294002-treated TR β cells compared to the EV control (Figure 8B).

In addition to the Akt-mTOR-p70S6K axis, we also observed an increase in pGYS1 following both T₃ and LY294002 or buparlisib treatment in our cells, suggesting a robust Akt suppression due to TR β activation in SW1736 cells (Fig. 8C and Supplemental Fig. 5B). Finally, these results appeared to be dependent on long-term T₃ treatment, as short-term T₃ exposure failed to significantly enhance suppression of PI3K with TR β or LY294002 (Fig. 9A and B).

4. Discussion

TR β has shown to be a potent tumor suppressor in several types of cancer including breast and thyroid cancer (15,16,35,36). However, there are only a few tumor suppressive mechanisms delineated in the literature, which include TR β -mediated JAK1/STAT1 activation and binding to p85 α (15,20,35). Multiple groups have shown the potential for TR β to bind p85 α in the cytoplasm, inhibiting PI3K-mediated PIP₂ to PIP₃ catalysis. While TR β and T₃ failed to rapidly inhibit PI3K activity in these ATC cells, transcriptomic data revealed novel genomic mechanisms of TR β -mediated PI3K suppression. Intriguingly, negatively regulated genes included RTKs such as FGFR isoforms and HER3, both of which are implicated in advanced thyroid carcinomas (37-39). TR β -mediated downregulation of HER3 is particularly interesting, as HER3 is the most potent activating binding partner of HER2 and was found to promote PI3K inhibitor resistance (40,41). In addition to regulating expression of upstream regulators of PI3K, TR β increased expression of membrane-associated phosphatases, including *INPP5J* and *INPP4B*. *INPP4B* has shown to exhibit remarkable tumor suppression in an *in vivo* model of thyroid cancer by regulating PI3K signaling

(42). Furthermore, TR β also increased expression of the phosphatases *PTPL1*, *PHLPP1*, and the R5B subunit of PPP2. These phosphatases preferentially dephosphorylate ser473 on Akt, and INPP4B and INPP5J modulate ser473 phosphorylation levels (28-30). Increased expression of these phosphatases would account for the robust decrease in ser473 phosphorylation but not thr308 and further supports the notion that TR β -mediated suppression of the PI3K pathway in these cells is primarily driven by transcriptional regulation. Importantly, both Akt residues must be phosphorylated for maximum activity, as thr308 phosphorylation accounts for only 10% of Akt activity (43). Therefore, the robust pAkt ser473 dephosphorylation may be sufficient to inhibit Akt activity, accounting for the growth and migration inhibition observed in this study. Downstream consequences of TR β -mediated dephosphorylation of Akt was observed in three well-established downstream targets of Akt, including GYS1, mTOR, and p70S6K. In addition to the previously documented mechanisms of TR β tumor suppression, genomic regulation of PI3K regulators likely drives a reduction in cell viability and migration. TR β enhanced the effect of PI3K inhibitors LY294002 and buparlisib as shown by decreased cell viability, migration, and cell signaling. Importantly, in a phase II trial of ATC patients, buparlisib was able to reduce tumor burden and modestly improve patient survival (44). As we have observed an enhanced response to PI3K inhibitors in the presence of TR β and hormone, it would be worthwhile to determine if expression levels of TR β in patient tumors were correlated with patient outcomes. In summary, our results demonstrate that TR β suppresses PI3K signaling in SW1736 cells by genomic regulation of RTKs and phosphatases. Although the potential for TR β to suppress PI3K signaling by binding to the p85 α subunit in the cytoplasm is well known, this is the first report to

highlight genomic mechanisms by which TR β suppresses the PI3K-Akt-mTOR axis. The presence and activation of TR β in ATC cells may be a promising therapeutic target to constrain tumor progression and resistance to chemotherapeutics.

Acknowledgments

The SW1736 and KTC-2 cell lines were generously provided by Dr. John Copland III (Mayo Clinic), and 8505C, OCUT-2, and CUTC60 cells were generously provided by Dr. Rebecca Schweppe (University of Colorado). Human cell line authentication, NextGen sequencing, automated DNA sequencing and molecular imaging was performed in the Vermont Integrative Genomics Resource supported by the University of Vermont Cancer Center, Lake Champlain Cancer Research Organization, and the UVM Larner College of Medicine. Additional human cell line authentication was performed by the CU Cancer Center Tissue Culture Shared Resource supported by NCI P30CA046934. Lentiviral constructs were made with the assistance of Dr. Jon Ramsey, University of Vermont (UVM) Cancer Translational Research Laboratory, UVM. Biorender vector graphics software was used to generate Figure 3A. We thank Dr. Jane Lian for early conceptualization and design of this project. We thank Dr. Eyal Amiel for his generous donation of several antibodies and for support on the manuscript discussion.

References

1. Pereira M, Williams VL, Hallanger Johnson J, Valderrabano P. Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations. *Thyroid : official journal of the American Thyroid Association*. 2020.
2. Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. *Head & neck*. 2016;38 Suppl 1:E2083-2090.
3. Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M,

- Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. *The Journal of clinical endocrinology and metabolism*. 2017;102(12):4506-4514.
4. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. *Nature reviews Cancer*. 2013;13(3):184-199.
5. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. *Annals of medicine*. 2014;46(6):372-383.
6. Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. *Molecular biology reports*. 2020;47(6):4587-4629.
7. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. *The Journal of clinical endocrinology and metabolism*. 2008;93(8):3106-3116.
8. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. *The Journal of clinical endocrinology and metabolism*. 2008;93(1):278-284.
9. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. *The Journal of clinical endocrinology and metabolism*. 2007;92(6):2387-2390.
10. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. *Cancer research*. 1997;57(21):4710-4713.
11. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. *Oncogene*. 2005;24(50):7482-7492.
12. Cao X, Kambe F, Yamauchi M, Seo H. Thyroid-hormone-dependent activation of the phosphoinositide 3-kinase/Akt cascade requires Src and enhances neuronal survival. *Biochem J*. 2009;424(2):201-209.
13. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen NH, Scanlan TS, Moskowitz MA, Cheng SY, Liao JK. Rapid nongenomic actions of thyroid hormone. *Proc Natl Acad Sci U S A*. 2006;103(38):14104-14109.
14. Carr FE, Tai PW, Barnum MS, Gillis NE, Evans KG, Taber TH, White JH, Tomczak JA, Jaworski DM, Zaidi SK, Lian JB, Stein JL, Stein GS. Thyroid Hormone Receptor-beta (TRbeta) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer. *Endocrinology*. 2016;157(8):3278-3292.
15. Bolf EL, Gillis NE, Davidson CD, Rodriguez PD, Cozzens L, Tomczak JA, Frietze S, Carr FE. Thyroid Hormone Receptor Beta Induces A Tumor Suppressive Program In Anaplastic Thyroid Cancer. *Molecular cancer research : MCR*. 2020.
16. Kim WG, Zhao L, Kim DW, Willingham MC, Cheng SY. Inhibition of tumorigenesis by the thyroid hormone receptor beta in xenograft models. *Thyroid : official journal of the American Thyroid Association*. 2014;24(2):260-269.
17. Martin NP, Marron Fernandez de Velasco E, Mizuno F, Scappini EL, Gloss B, Erxleben C, Williams JG, Stapleton HM, Gentile S, Armstrong DL. A rapid cytoplasmic mechanism for PI3 kinase regulation by the nuclear thyroid hormone receptor, TRbeta, and genetic evidence for its

- role in the maturation of mouse hippocampal synapses in vivo. *Endocrinology*. 2014;155(9):3713-3724.
18. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennstrom B, Aranda A. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. *Cancer research*. 2009;69(2):501-509.
19. Park JW, Zhao L, Willingham M, Cheng S-y. Oncogenic mutations of thyroid hormone receptor β . *Oncotarget*. 2015;6(10):8115-8131.
20. Furuya F, Hanover JA, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. *Proc Natl Acad Sci U S A*. 2006;103(6):1780-1785.
21. Kato Y, Ying H, Willingham MC, Cheng SY. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis. *Endocrinology*. 2004;145(10):4430-4438.
22. Gillis NE, Taber TH, Bolf EL, Beaudet CM, Tomczak JA, White JH, Stein JL, Stein GS, Lian JB, Frietze S, Carr FE. Thyroid Hormone Receptor β Suppression of RUNX2 is Mediated by Brahma Related Gene 1 Dependent Chromatin Remodeling. *Endocrinology*. 2018;en.2018-00128-en.02018-00128.
23. Verga Falzacappa C, Petrucci E, Patriarca V, Michienzi S, Stigliano A, Brunetti E, Toscano V, Misiti S. Thyroid hormone receptor TRbeta1 mediates Akt activation by T3 in pancreatic beta cells. *Journal of molecular endocrinology*. 2007;38(1-2):221-233.
24. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell*. 2007;129(7):1261-1274.
25. Domoto T, Pyko IV, Furuta T, Miyashita K, Uehara M, Shimasaki T, Nakada M, Minamoto T. Glycogen synthase kinase-3 β is a pivotal mediator of cancer invasion and resistance to therapy. *Cancer Sci*. 2016;107(10):1363-1372.
26. Orlandella FM, Mariniello RM, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, Denaro M, Basolo F, Salvatore G. Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 α/β pathways. *Mol Carcinog*. 2019;58(7):1181-1193.
27. Toker A, Rameh L. PIPping on AKT1: How Many Phosphatases Does It Take to Turn off PI3K? *Cancer cell*. 2015;28(2):143-145.
28. O'Neill AK, Niederst MJ, Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. *The FEBS journal*. 2013;280(2):572-583.
29. Kimber WA, Deak M, Prescott AR, Alessi DR. Interaction of the protein tyrosine phosphatase PTPL1 with the PtdIns(3,4)P₂-binding adaptor protein TAPP1. *Biochem J*. 2003;376(Pt 2):525-535.
30. Beg M, Srivastava A, Shankar K, Varshney S, Rajan S, Gupta A, Kumar D, Gaikwad AN. PPP2R5B, a regulatory subunit of PP2A, contributes to adipocyte insulin resistance. *Molecular and cellular endocrinology*. 2016;437:97-107.
31. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. *Proc Natl Acad Sci U S A*. 2005;102(52):19075-19080.
32. Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin

- 486 JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid
487 cancers. *J Clin Invest.* 2016;126(3):1052-1066.
- 488 33. Wojtas B, Pfeifer A, Oczko-Wojciechowska M, Krajewska J, Czarniecka A, Kukulska A,
489 Eszlinger M, Musholt T, Stokowy T, Swierniak M, Stobiecka E, Chmielik E, Rusinek D, Tyszkiewicz
490 T, Halczok M, Hauptmann S, Lange D, Jarzab M, Paschke R, Jarzab B. Gene Expression (mRNA)
491 Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours. *Int J Mol*
492 *Sci.* 2017;18(6).
- 493 34. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K)
494 inhibitors as cancer therapeutics. *J Hematol Oncol.* 2013;6(1):88.
- 495 35. Furuya F, Lu C, Willingham MC, Cheng SY. Inhibition of phosphatidylinositol 3-kinase
496 delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
497 *Carcinogenesis.* 2007;28(12):2451-2458.
- 498 36. López-Mateo I, Alonso-Merino E, Suarez-Cabrera C, Park JW, Cheng SY, Alemany S,
499 Paramio JM, Aranda A. Thyroid Hormone Receptor β Inhibits Self-Renewal Capacity of Breast
500 Cancer Stem Cells. *Thyroid : official journal of the American Thyroid Association.*
501 2020;30(1):116-132.
- 502 37. Kasaian K, Wiseman SM, Walker BA, Schein JE, Zhao Y, Hirst M, Moore RA, Mungall AJ,
503 Marra MA, Jones SJ. The genomic and transcriptomic landscape of anaplastic thyroid cancer:
504 implications for therapy. *BMC cancer.* 2015;15:984.
- 505 38. Yamazaki H, Yokose T, Hayashi H, Iwasaki H, Osanai S, Suganuma N, Nakayama H,
506 Masudo K, Rino Y, Masuda M. Expression of fibroblast growth factor receptor 4 and clinical
507 response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study. *Eur J Clin*
508 *Pharmacol.* 2020;76(5):703-709.
- 509 39. Cheng L, Jin Y, Liu M, Ruan M, Chen L. HER inhibitor promotes BRAF/MEK inhibitor-
510 induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. *Oncotarget.*
511 2017;8(12):19843-19854.
- 512 40. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of
513 HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. *Proc Natl*
514 *Acad Sci U S A.* 2012;109(8):2718-2723.
- 515 41. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunakaran D, Lavi S, Ratzkin BJ, Yarden Y.
516 A hierarchical network of interreceptor interactions determines signal transduction by Neu
517 differentiation factor/neuregulin and epidermal growth factor. *Mol Cell Biol.* 1996;16(10):5276-
518 5287.
- 519 42. Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C,
520 Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP. In Vivo Role of INPP4B
521 in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.
522 *Cancer Discov.* 2015;5(7):740-751.
- 523 43. Fayard E, Tintignac LA, Baudry A, Hemmings BA. Protein kinase B/Akt at a glance. *Journal*
524 *of cell science.* 2005;118(Pt 24):5675-5678.
- 525 44. Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, Do Cao C,
526 Leboulleux S, Klein M, Tabarin A, Eberle MC, Benisvy D, de la Fouchardiere C, Bournaud C,
527 Lasolle H, Delahaye A, Rabilloud M, Lapras V, Decaussin-Petrucci M, Schlumberger M. Effect of
528 Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid
529 Cancer. *Thyroid : official journal of the American Thyroid Association.* 2018;28(9):1174-1179.

45. Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. *Cell*. 2017;169(3):381-405.
46. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. *Cell*. 2011;144(5):757-768.
47. Xu JH, Zhao JX, Jiang MY, Yang LP, Sun ML, Wang HW. MiR-193 promotes cell proliferation and invasion by ING5/PI3K/AKT pathway of triple-negative breast cancer. *Eur Rev Med Pharmacol Sci*. 2020;24(6):3122-3129.
48. Mahajan K, Mahajan NP. ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. *Oncogene*. 2015;34(32):4162-4167.
49. Laplante M, Sabatini DM. mTOR signaling at a glance. *Journal of cell science*. 2009;122(Pt 20):3589-3594.
50. Jia J, Abudu YP, Claude-Taupin A, Gu Y, Kumar S, Choi SW, Peters R, Mudd MH, Allers L, Salemi M, Phinney B, Johansen T, Deretic V. Galectins Control mTOR in Response to Endomembrane Damage. *Mol Cell*. 2018;70(1):120-135.e128.
51. Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2019.

Graphical abstract

Figure 1. Short-term or no exposure to T₃ is insufficient for TRβ-mediated PI3K suppression. SW1736-EV (EV) and SW1736-TRβ (TRβ) cells were treated with 10 nM T₃ or vehicle (1 N NaOH) for 30 min before protein levels were determined by immunoblot (**A**) or incubated with anti-p85α antibody for PI3K catalysis ELISA (**B**). ELISA signal in **B** was standardized to protein concentration as determined by a Bradford assay. Significance in **B** was calculated by two-way ANOVA followed by Tukey multiple comparisons test. ns = no significance (p ≥ 0.05) across treatment groups.

565

Figure 2: Long-term T₃ with TRβ inhibits the PI3K-Akt-mTOR pathway in SW1736 cells. SW1736-EV (EV) and SW1736-TRβ (TRβ) cells were treated with 10 nM T₃ for 24 hours before protein levels were determined by immunoblot (**A** and **C**) or subjugated to a pAkt Ser473 sandwich ELISA (**B**). The samples in **A** are replicates. Dashed lines in immunoblots indicate gap between two sets of lanes on the same membrane. ELISA signal in **B** was standardized to protein concentration as determined by a Bradford assay. Significance in **B** was calculated by Student's t-test. (*p < 0.05).

A

B

C

Figure 3: Liganded-TRβ decreases expression of oncogenic genes and increases tumor suppressive genes in the PI3K-Akt-mTOR signaling axis. A. RTKs dimerize in response to ligand to allow for IRS2 to dock and recruit PI3K (45). PI3K phosphorylates PI(4,5)P₂ to PIP₃. PTEN and INPP5J dephosphorylate PIP₃ to PI(4,5)P₂ and PI(3,4)P₂ respectively. INPP4B dephosphorylates PI(3,4)P₂ to PI(3)P. PIP₃ recruits PDK1 (not shown) and Akt to the plasma membrane for PDK1 phosphorylation of Akt T308. NIP7-activated mTORC2 phosphorylates Akt S473, which is dephosphorylated by PHLPP1 (46). ING5 has been shown to dephosphorylate Akt in hormone-dependent cancers (47). The 2R5B subunit of PPP2 directs the complex to dephosphorylate Akt T308 and S473 (30). TNK2 phosphorylates Akt Y176 to enhance plasma membrane recruitment

(48). Akt leads to the activation of mTORC1 by TSC 1/2-Rheb (not shown). Nix and PML destabilize Rheb-mTORC1 binding (49). Galectin-8 inhibits and delocalizes mTORC1 (50). GSK3 β is inhibited by Akt and inhibits multiple substrates relevant to glucose and glycogen metabolism, survival signaling, and cell cycle progression. mTORC1 phosphorylates and inhibits 4E-BP1 which inhibits EIF4E. MTORC1 also activates P70S6K which inhibits GSK3 β and PDCD4 and activates EIF4B and RPS6. EIF4B and PDCD4 regulate EIF4A (49). **B.** Ligand-bound TR β decreased expression of receptor tyrosine kinases. **C.** Ligand-bound TR β increased expression of PI3K-Akt phosphatases. Significance and fold change values between EV+T₃ and TR β +T₃ are located in Supplementary Table 1.

Figure 4: TR β expression correlates with low Akt ser473 phosphorylation and high phosphoinositide and Akt phosphatase expression. ATC cell lines were analyzed for TR β and pAkt ser473 expression (**A and B**) and phosphoinositide and Akt phosphatases (**C**). Dashed line in immunoblot indicates gap between two sets of lanes on the same membrane. Significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test (* $p < 0.05$, ** $p < 0.01$).

Figure 5: PI3K signaling genes regulated by TR β in SW1736 cells are aberrantly expressed in patient thyroid cancer samples. Patient thyroid cancer microarray data (GSE76039, GSE3467, GSE82208) were analyzed for genes encoding receptor tyrosine kinases (A), phosphoinositide and Akt phosphatases (B), and TR β , enzymes, and transporters necessary for synthesizing thyroid hormones. Significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test (ns = no significance $p \geq 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). Normal n = 9. PTC n = 9, FTC n = 27, PDTC n = 17, ATC n = 20

Figure 6: TRβ and T₃ reduce cell viability and migration in serum-activated SW1736 cells.

A. SW1736-EV (EV) and SW1736-TRβ (TRβ) cells were treated with 10 nM T₃ or vehicle (1 N NaOH) for four days. Each day the cells were lifted with trypsin and counted using a hemocytometer for viable cells. Area under the curve (AUC) analysis was performed (**B**) and normalized to the EV-T₃ group. Significance was calculated using one-way ANOVA followed by Tukey's multiple comparisons test (* p < 0.05, ** p < 0.01, ***p < 0.001, **** p < 0.0001). **C.** EV and TRβ cells were grown to confluency in 6 well plates before treatment with 10 μg/ml mitomycin C for 2.5 hours. Media were aspirated, and the cells were scratched with a P1000 pipette tip before being washed with PBS and treated with media containing 10 nM T₃. **D.** Wells were imaged each day and % wound closure relative to day 1 was calculated. **E.** Area under the curve (AUC) analysis was performed and normalized to the EV group. Significance was calculated using Student's t-test test. ** p < 0.01.

Figure 7: The effect of LY294002 on cytotoxicity and migration is enhanced in SW1736-TR β cells.

A. EV and TR β cells were treated with 10 nM T $_3$ and LY294002 (0.1-50 μM) or matched-concentration vehicle (100% EtOH) for four days. Each day the cells were lifted with trypsin and counted using a hemocytometer for viable cells. Area the curve analysis was conducted for each LY294002 concentration to calculate % cytotoxicity relative to EV vehicle at each concentration of LY294002. EC50 values were calculated using GraphPad Prism's nonlinear regression package.

B. EV and TR β cells were grown to confluency in 6 well plates before treatment with 10 $\mu\text{g}/\text{ml}$ mitomycin C for 2.5 hours. Media were aspirated, and the cells were scratched with a P1000 pipette tip before being washed with PBS and treated with media containing 10 nM T $_3$ and 1 or 10 μM LY294002.

C. Wells were imaged each day and % wound closure relative to day 1 was calculated.

D. Area under the curve (AUC) analysis was performed and normalized to the EV 1 μM LY294002 group. Significance was calculated using one-way ANOVA followed by Tukey's multiple comparisons test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Figure 8: TRβ enhances LY294002-mediated inactivation of the PI3K-Akt-mTOR axis.

SW1736-EV (EV) and SW1736-TRβ (TRβ) cells were treated with 10 nM T₃ for 24 hours before 1 hour of LY294002 (LY) treatment (**A** and **C**: 10 μM, **B**: 0, 1, or 10 μM). Protein levels were determined by immunoblot (**A** and **C**) or subjugated to a pAkt Ser473 sandwich ELISA (**B**). Samples in **A** are replicates. Dashed lines in immunoblots indicate gap between two sets of lanes on the same membrane. ELISA signal in **B** was standardized to protein concentration as determined by a Bradford assay. Significance in **B** was calculated by one-way ANOVA followed by Sidak's multiple comparison test. (*p < 0.05, ***p < 0.001).

Figure 9. Short-term or no exposure to T₃ is insufficient for TR β to enhance LY294002 suppression of PI3K.

SW1736-EV (EV) and SW1736-TR β (TR β) cells were treated with 10 nM T₃ or vehicle (1 N NaOH) for 30 min before 1 hour of 10 μ M LY294002 (LY) treatment. Protein levels were determined by immunoblot (A) or incubated with anti-p85 α antibody for PI3K catalysis ELISA (B). ELISA signal in B was standardized to protein concentration as determined by a Bradford assay. Significance in B was calculated by two-way ANOVA followed by Tukey multiple comparisons test. ns = no significance ($p \geq 0.05$) across treatment groups.